OptiBiotix signs distribution deal with Cambridge Commodities
By Josh White
Date: Monday 01 Jun 2020
(Sharecast News) - OptiBiotix Health announced on Monday that its wholly-owned subsidiary ProBiotix Health has entered into a non-exclusive distribution agreement with Cambridge Commodities (CCL) for the distribution of 'LPLDL' and 'CholBiome x3' in the UK.
The AIM-traded firm said the agreement granted CCL a non-exclusive licence to distribute ProBiotix's specialty ingredient LPLDL, as well as the finished dietary supplement CholBiome x3 for cholesterol and blood pressure reduction.
It described CCL as "one of the UK's leading" specialty ingredients suppliers, explaining that the agreement extended the commercial reach of LPLDL into new application areas where CCL has specific sector expertise.
Those areas included food and beverage, sports nutrition, health and wellbeing, and beauty.
The board said the agreement would build on OptiBiotix's existing relationship with CCL, which led to the successful launch of SlimBiome in Holland and Barrett.
"We are pleased to announce the signing of the distribution agreement with CCL," said ProBiotix commercial director Mikkel Hvid-Hansen.
"We chose them due to their leading market position and expertise in commercialising value added speciality ingredients like LPLDL and CholBiome x3 to major UK retailers and supplement companies"
Hvid-Hansen said the company believed working with CCL, and similar partners, provided the best opportunity to expand the range of applications for LPLDL and CholBiome x3 to a "wide variety" of industry sectors.
"This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors."
At 1556 BST, shares in OptiBiotix Health were down 2.52% at 58p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN